BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 17117660)

  • 1. [Can higher level of HDL cholesterol augment cardiovascular disease prevention? The combination statins-nicotinic acid increases the level of HDL and reduces the level of LDL cholesterol].
    Carlson LA
    Lakartidningen; 2006 Oct 25-31; 103(43):3283-5. PubMed ID: 17117660
    [No Abstract]   [Full Text] [Related]  

  • 2. [Considerable remaining risk in unchecked LDL lowering. Is the HDL increase the way out?].
    MMW Fortschr Med; 2006 Jun; 148(24):6, 8. PubMed ID: 16856232
    [No Abstract]   [Full Text] [Related]  

  • 3. [Safety and tolerability of nicotinic acid. Results of the multicenter, open, prospective NAUTILUS study].
    Vogt A; Kassner U; Hostalek U; Peiter A; Steinhagen-Thiessen E
    MMW Fortschr Med; 2006 May; 148(18):41. PubMed ID: 16736688
    [No Abstract]   [Full Text] [Related]  

  • 4. Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk.
    Brown BG; Zhao XQ
    Am J Cardiol; 2008 Apr; 101(8A):58B-62B. PubMed ID: 18375243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [LDL lowering--level and time. Maybe two equally important parameters for protection against arteriosclerosis].
    Herlitz J
    Lakartidningen; 2006 Oct 25-31; 103(43):3272-3. PubMed ID: 17117658
    [No Abstract]   [Full Text] [Related]  

  • 6. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statins. Cholesterol treatment and beyond.
    Mayo Clin Health Lett; 2004 Nov; 22(11):1-3. PubMed ID: 15619748
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of high-risk older persons with lipid-lowering drug therapy.
    Aronow WS
    Am J Ther; 2008; 15(2):102-7. PubMed ID: 18356628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Focus on HDL as a therapeutic target for CAD risk reduction.
    Davidson MH
    Am J Cardiol; 2009 Nov; 104(10 Suppl):1E-2E. PubMed ID: 19895937
    [No Abstract]   [Full Text] [Related]  

  • 10. [Strengthened support for statin therapy as secondary prevention. Doubtful evidence for more intensive lowering of cholesterol levels].
    HÃ¥kansson J
    Lakartidningen; 2011 Jun 1-14; 108(22-23):1234-5. PubMed ID: 21786497
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical trials and tribulations. Cholesterol veers off script.
    Couzin J
    Science; 2008 Oct; 322(5899):220-3. PubMed ID: 18845747
    [No Abstract]   [Full Text] [Related]  

  • 12. Goals for cholesterol lowering.
    Stankler L
    Circulation; 1999 May; 99(18):2477. PubMed ID: 10318741
    [No Abstract]   [Full Text] [Related]  

  • 13. [The TNT debate gives a lift to the debate about high-dose statins. Lower LDL cholesterol levels further reduce the cardiovascular risk].
    Olsson AG
    Lakartidningen; 2005 May 2-15; 102(18-19):1393-4. PubMed ID: 15929421
    [No Abstract]   [Full Text] [Related]  

  • 14. [Lower LDL and/or raise HDL. In what direction is lipidology moving?].
    Parhofer KG
    MMW Fortschr Med; 2007 May; 149(22):27. PubMed ID: 18069222
    [No Abstract]   [Full Text] [Related]  

  • 15. Drug insight: the role of statins in combination with ezetimibe to lower LDL cholesterol.
    Gotto AM; Farmer JA
    Nat Clin Pract Cardiovasc Med; 2006 Dec; 3(12):664-72. PubMed ID: 17122799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nicotinic acid: new/old drug. Immediate or sustained release: too risky for a drug with no proven benefit.
    Prescrire Int; 2006 Dec; 15(86):213-6. PubMed ID: 17165243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Can cardiovascular events be prevented by raising HDL cholesterol?].
    Langslet G; Reikvam A
    Tidsskr Nor Laegeforen; 2008 Jun; 128(13):1519-23. PubMed ID: 18587459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Better with lower LDL cholesterol! Aim at 2 mmol/l for secondary prevention].
    Olsson AG
    Lakartidningen; 2006 Jan 11-17; 103(1-2):22-3. PubMed ID: 16465841
    [No Abstract]   [Full Text] [Related]  

  • 19. Modification of coronary atherosclerosis.
    Druck MN
    Can J Cardiol; 1993 Mar; 9(2):162-4. PubMed ID: 8490786
    [No Abstract]   [Full Text] [Related]  

  • 20. [Ezetimib--the first selective cholesterol resorption inhibitors. Strengthening of statins].
    MMW Fortschr Med; 2002 Nov; 144(48):52-3. PubMed ID: 12532546
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.